白蛋白结合型紫杉醇在晚期恶性肿瘤三线及以上化疗中的效果及安全性  

The efficacy and safety of albumin-bound paclitaxel in more than the third-line chemotherapy for advanced malignance

作　　者：王贻军[1] 甘立菁[1] 许慎[1] 

机构地区：[1]福建医科大学附属漳州市医院肿瘤内科,363000

出　　处：《肿瘤研究与临床》2014年第8期541-543,共3页Cancer Research and Clinic

摘　　要：目的 观察白蛋白结合型紫杉醇在晚期恶性肿瘤三线及以上化疗中的近期疗效及安全性.方法 晚期恶性肿瘤患者34例,所有患者均经病理检查证实,既往化疗失败后接受含白蛋白结合型紫杉醇方案三线以上（含三线）化疗,观察疗效及安全性.结果 34例患者共完成110个周期化疗,每例平均3.24个周期.无完全缓解（CR）患者,部分缓解（PR） 12例,稳定（SD）9例,进展（PD） 13例.客观缓解率（ORR） 35.29％（12/34）,疾病控制率（DCR） 61.76 ％（21/34）.主要不良反应为血液学毒性,其中粒细胞减少26例（76.47％）,贫血14例（41.18％）,血小板减少3例（8.82％）.其他常见不良反应有脱发27例（79.41％）,肌肉关节痛15例（44.18％）.结论 白蛋白结合型紫杉醇在晚期恶性肿瘤三线以上（含三线）化疗中客观缓解率高,不良反应可耐受.Objective To observe the efficacy and safety of albumin-bound paclitaxel on the patients with advanced malignance in more than the third-lines （including the third-lines）.Methods 34 patients with advanced malignance diagnosed by pathological evidence accepted more than the third-lines （including the third-lines） chemotherapy containing albumin-bound paclitaxel after failure of chemotherapy.The efficacy and safety were observed.Results Totally 110 cycles chemotherapy were completed,with a mean of 3.24 cycles in each of the 34 patients.No CR patients,12 cases of PR,9 cases of SD and 13 cases of PD were found.The response rate （RR） was 35.29 % （12/34） and the disease control rate （DCR） was 61.76 % （21/34）.The main toxicity was hematologic toxicity,including neutropenia in 26 cases （76.47 %）,anemia in 14 cases （41.18 %） and thrombocytopenia in 3 cases （8.82 %）.Other common adverse reactions included alopecia in 27 patients （79.41%） and muscle and joint pain in 15 cases （44.18 %）.Conclusions The albumin-bound paclitaxel is effective and tolerable in patients with advanced malignance in more than the third-lines （include the thirdlines） chemotherapy.

关 键 词：白蛋白结合型紫杉醇 恶性肿瘤 三线化疗 疗效 安全性 

分 类 号：R273[医药卫生—中西医结合]